Esketamine

Generic Name
Esketamine
Brand Names
Spravato
Drug Type
Small Molecule
Chemical Formula
C13H16ClNO
CAS Number
33643-46-8
Unique Ingredient Identifier
50LFG02TXD
Background

Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...

Indication

Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.

Associated Conditions
Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Pain
Associated Therapies
Intubation

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Not Applicable
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-10-03
Last Posted Date
2024-10-07
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
568
Registration Number
NCT06624878

Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery

First Posted Date
2024-09-23
Last Posted Date
2024-11-07
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
142
Registration Number
NCT06608030
Locations
🇨🇳

Beijing Tiantan Hospital, Bejing, Beijing, China

🇨🇳

First Medical center of Chinese PLA General Hospital, Beijing, Beijing, China

Dexmedetomidine-esketamine Combined Nasal Administration and Emergence Delirium

First Posted Date
2024-08-22
Last Posted Date
2024-08-22
Lead Sponsor
Peking University First Hospital
Target Recruit Count
340
Registration Number
NCT06566469
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

The Effect of Subclinical Dose of Ketamine on Early Postoperative Pain Sensitivity in Patients Undergoing Salpingectomy

Early Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-08-19
Last Posted Date
2024-08-19
Lead Sponsor
Fujian Provincial Hospital
Target Recruit Count
60
Registration Number
NCT06559280

Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease

First Posted Date
2024-08-09
Last Posted Date
2024-08-09
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
102
Registration Number
NCT06543563
Locations
🇨🇳

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2024-07-31
Last Posted Date
2024-08-22
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
180
Registration Number
NCT06530706
Locations
🇨🇳

Zhejiang cancer hospital, Hangzhou, Zhejiang, China

Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2024-06-11
Last Posted Date
2024-06-14
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
156
Registration Number
NCT06451627
Locations
🇨🇳

Beijing Tian Tan Hospital, Beijing, China

Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2024-05-28
Last Posted Date
2024-08-05
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
150
Registration Number
NCT06430645
Locations
🇨🇳

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

Behavioural Activation Therapy and Esketamine for Resistant Depression

First Posted Date
2024-05-28
Last Posted Date
2024-11-14
Lead Sponsor
The Royal's Institute of Mental Health Research
Target Recruit Count
40
Registration Number
NCT06431386
Locations
🇨🇦

The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada

Esketamine and Butorphanol for Post-Lobectomy Pain

First Posted Date
2024-05-03
Last Posted Date
2024-05-06
Lead Sponsor
Second People's Hospital of Hefei City
Target Recruit Count
223
Registration Number
NCT06398834
Locations
🇨🇳

The Second People's Hospital of Hefei, Hefei, Anhui, China

© Copyright 2024. All Rights Reserved by MedPath